These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18319715)

  • 1. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
    Bianco R; Garofalo S; Rosa R; Damiano V; Gelardi T; Daniele G; Marciano R; Ciardiello F; Tortora G
    Br J Cancer; 2008 Mar; 98(5):923-30. PubMed ID: 18319715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
    Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
    BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
    Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
    PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
    Gelardi T; Caputo R; Damiano V; Daniele G; Pepe S; Ciardiello F; Lahn M; Bianco R; Tortora G
    Br J Cancer; 2008 Aug; 99(3):473-80. PubMed ID: 18665191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
    Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
    J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
    La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG
    Biochem Pharmacol; 2009 Sep; 78(5):460-8. PubMed ID: 19427302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
    Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
    Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
    D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
    Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
    Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
    Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
    Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
    Castillo-Pichardo L; Dharmawardhane SF
    Nutr Cancer; 2012; 64(7):1058-69. PubMed ID: 23061908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
    Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
    Schmid K; Bago-Horvath Z; Berger W; Haitel A; Cejka D; Werzowa J; Filipits M; Herberger B; Hayden H; Sieghart W
    Br J Cancer; 2010 Aug; 103(5):622-8. PubMed ID: 20683448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
    Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatment combinations: integrating therapy into clinical practice.
    Wong ST
    Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S9-S14. PubMed ID: 19923318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.